An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Doses Of PF-04447943 Up To An Exposure Cap In Healthy Elderly Subjects.

Trial Profile

An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Doses Of PF-04447943 Up To An Exposure Cap In Healthy Elderly Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs PF 4447943 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Dec 2017 Results assessing safety and tolerability of PF-04447943 across a clinical trial program in 277 patients (Eight phase 1 studies, One phase II and One phase Ib study) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Jul 2010 Tolerability results presented at the 2010 International Conference on Alzheimer's Disease and Related Disorders.
    • 16 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top